Literature DB >> 10708963

Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis.

S J Kim1, Y H Im, S D Markowitz, Y J Bang.   

Abstract

Signals from the TGF-betas are mediated by the TGF-beta receptors and their substrates, the Smad proteins. Inactivation of either of the two transmembrane serine/threonine kinases called the TGF-beta type I and type II receptors is now known to underlie a wide variety of human pathologies including, especially carcinogenesis. Numerous studies have now demonstrated that the TGF-beta receptor complex and its downstream signaling intermediates constitute a tumor suppressor pathway. We review here a specific pathway of mutational inactivation of the TGF-beta type II receptor resulting from microsatellite instability and demonstrate that, by contrast, the most common mechanism of loss of expression of the TGF-beta type II receptor involves transcriptional repression. This provides a new target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708963     DOI: 10.1016/s1359-6101(99)00039-8

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  43 in total

Review 1.  Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia.

Authors:  Razi Khan; Richard Sheppard
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

Review 2.  The two faces of transforming growth factor beta in carcinogenesis.

Authors:  Anita B Roberts; Lalage M Wakefield
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-14       Impact factor: 11.205

Review 3.  Missing link between microRNA and prostate cancer.

Authors:  Balraj Singh Gill; Jimi Marin Alex; Sanjeev Kumar
Journal:  Tumour Biol       Date:  2016-01-28

Review 4.  Emerging cytokine networks in colorectal cancer.

Authors:  Nathan R West; Sarah McCuaig; Fanny Franchini; Fiona Powrie
Journal:  Nat Rev Immunol       Date:  2015-09-11       Impact factor: 53.106

5.  The aberrant methylation of TSP1 suppresses TGF-beta1 activation in colorectal cancer.

Authors:  Andres Rojas; Shereen Meherem; Young-Ho Kim; Mary Kay Washington; Joseph E Willis; Sanford D Markowitz; William M Grady
Journal:  Int J Cancer       Date:  2008-07-01       Impact factor: 7.396

Review 6.  Restoring TGFβ1 pathway-related microRNAs: possible impact in metastatic prostate cancer development.

Authors:  Juliana Inês Santos; Ana Luísa Teixeira; Francisca Dias; Mónica Gomes; Augusto Nogueira; Joana Assis; Rui Medeiros
Journal:  Tumour Biol       Date:  2014-04-25

7.  The endogenous ratio of Smad2 and Smad3 influences the cytostatic function of Smad3.

Authors:  Sang Gyun Kim; Hyun-Ah Kim; Hyun-Soon Jong; Jung-Hyun Park; Noe Kyeong Kim; Seung Hwan Hong; Tae-You Kim; Yung-Jue Bang
Journal:  Mol Biol Cell       Date:  2005-08-10       Impact factor: 4.138

Review 8.  A cytokine-mediated link between innate immunity, inflammation, and cancer.

Authors:  Wan-Wan Lin; Michael Karin
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 9.  Transforming growth factor beta (TGF-beta) and inflammation in cancer.

Authors:  Brian Bierie; Harold L Moses
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

10.  Transforming growth factor beta1 receptor II is downregulated by E1A in adenovirus-infected cells.

Authors:  Vera L Tarakanova; William S M Wold
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.